← SynDRA
PAZOPANIB
SynDRA canonical compound SYN0016262 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | PDGFRB |
|---|
| Mechanism of action | VEGFR inhibitor |
|---|
| Indication | renal cell carcinoma (RCC) | soft tissue sarcoma (STS) |
|---|
| Disease area | oncology |
|---|
All known targets
- KDR
- KIT
- PDGFRB
- FLT1
- FLT4
- FGFR1
- CSF1R
- PDGFRA
- FGFR3
- ITK
- LCK
- BRAF
Mechanisms of action (all sources)
- KIT INHIBITOR
- PDGFR inhibitor
- VEGFR inhibitor
- CSF1R INHIBITOR
- Macrophage colony stimulating factor receptor inhibitor
- Stem cell growth factor receptor inhibitor
- LCK INHIBITOR
- Tyrosine-protein kinase LCK inhibitor
- FGFR3 INHIBITOR
- Fibroblast growth factor receptor 3 inhibitor
- FGFR1 INHIBITOR
- Fibroblast growth factor receptor 1 inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- CA1
- CDK7
- PTK2
- AURKB
- CYP2C9
- CYP2D6
- TNK2
- CYP3A4
- ABCC4
- CA2
- CA12
- IGF1R
- PIK3CA
- PIK3CB
- PIK3CD
- PIK3C2G
- PIK3C2B
- PHKG2
- ABCB11
- PHKG1
- PIK3CG
- PFKP
- PEBP1
- PDXK
- PDPK1
- PARP1
- PAK6
- PAK5
- PAK4
- PGRMC1
- PIP4K2A
- PIM1
- PIM2
- PRKAR2A
- PRKAG2
- PRKAG1
- PRKACG
- PRKACB
- PRKACA
- PRKAA2
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- ACES
- MK10
- GLI3
- GNMT
- HNMT
- ITGAL
- KCC1A
- KSYK
- M3K10
- M3K11
- M3K9
- M4K3
- M4K4
- M4K5
- MK08
- MK09
- MP2K4
- ESRRA
- NF2L2
- NNMT
- NR1H4
- NR1I2
- NR1I3
- NSD2
- NTM1A
- NTMT1
- PNMT
- PPARD
- PPARG
- PRGR
- SMAD2
- SMAD3
- GAMT
- ESR1
- ADRB2
- CYP2C19
- AHR
- ANDR
- AVR2B
- COMT
Drug classes
- Protein Kinase Inhibitors
- Kinase Inhibitor
- Cytochrome P450 2D6 Inhibitors
- Cytochrome P450 3A4 Inhibitors
- Cytochrome P450 2C8 Inhibitors
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- PAZOPANIB HYDROCHLORIDE
- VOTRIENT
- Votrient
- GW786034B
- votrient
- GW 786034
- pazopanib hydrochloride
- pazopanib HCl
- GW-786034
- GW786034
- NSC-752782
- Pazopanib HCl
- Votrient (TN)
- NSC 752782
- 7RN5DR86CK
- GW 78603
- CHEBI:71219
- NCGC00188865-01
- Pazopanib [INN]
- Pazopanib (GW-786034)
- CAS-444731-52-6
- Pazopanib [INN:BAN]
- UNII-7RN5DR86CK
- pazopanibum
- HSDB 8210
- Pazopanib- Bio-X
- MFCD11616589
- GW 786034B
- indazolylpyrimidine 13
- Pazopanib (free base)
- Kinome_3790
- GW780604
- PAZOPANIB [MI]
- GW-780604
- PAZOPANIB [VANDF]
- Pazopanib-d6 (deuterated)
- PAZOPANIB [WHO-DD]
- PAZOPANIB [EMA EPAR]
Reported adverse events
- Alopecia
- Asthenia
- Bradycardia
- Cough
- Dizziness
- Dysgeusia
- Fatigue
- Fistula
- Gastrointestinal pain
- Headache
- Hypertension
- Hypothyroidism
Look up PAZOPANIB in the interactive SynDRA portal →